Our results are of clinical importance and warrant the implementation of PROX1 in future trials of adults with IDH-mutant astrocytomas to further establish its role as a prognostic biomarker and potential treatment target. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).